Alfred Clinical Trials

Alfred Health has more than 700 open trials across 20 clinical disciplines, our clinical trial portfolio is one of the largest in the country.

Clear filter
604 clinical trials found
Clinical trials

LOLIPOP

Long-Term Outcomes of Lidocaine Infusions for Post-Operative Pain: the LOLIPOP Trial (NCT05072314)

Currently recruiting

LuMIERE

LuMIERE: A Phase 1/2 Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor (NCT04939610)

Currently recruiting

BI 1036-0130

Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) (NCT06241573)

No longer recruiting

C1071005

MagnetisMM-5: An Open-Label, 3-Arm, Multicenter, Randomized Phase 3 Study To Evaluate The Efficacy And Safety Of Elranatamab (Pf-06863135) Monotherapy And Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone In Participants With Relapsed/Refractory Multiple Myeloma Who Have Received At Least 1 Prior Line Of Therapy Including Lenalidomide And A Proteasome Inhibitor (C1071005) (NCT05020236)

Currently recruiting

Magnitude Study

MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy [ATTR-CM] (NCT06128629)

Currently recruiting

MASTERPLAN

MASTERPLAN: A randomised phase II study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease (NCT04089150)

No longer recruiting

DAPA_HF

Mechanisms of action of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF) (ACTRN12621000187842)

Currently recruiting

MEL-SELF

MEL-SELF: A randomised controlled trial of a patient-led surveillance compared to clinician-led surveillance in people treated for early-stage melanoma (stage 0/I/II) (ACTRN12621000176864)

Currently recruiting

MelMarT

Melanoma Margins Trial (MelMarT): A Phase III, multi-centre, multi-national randominsed control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma (ACTRN12614000667617)

Currently recruiting

MEMENTO

MEMENTO - A Phase 4, Single-arm, Open-label Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Assess the Impact on Myocardial Structure with Cardiac Magnetic Resonance Imaging [CMR] (NCT06112743)

Currently recruiting

MY-PROMPT-2

More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures – MY-PROMPT-2 (TRU-MP2-22/AMaRC 22-02) (ACTRN12622001199707p)

Currently recruiting

MRDRIVE-ALL

MRDRIVE-ALL: Minimal Residual Disease Driven Intervention in Elderly Acute Lymphoblastic Leukaemia (Trial Not Registered)

Currently recruiting

MODUS

Multi-Organ Denervation to RedUce Sympathetic Drive, A Single Blinded, Multi-Center, Prospective Feasibility Study (MODUS Study) (ACTRN12620000412932)

Recently completed/closed

NADINA

Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma - NADINA (NCT04949113)

No longer recruiting

CALIPSO

Multicentre, adaptive, double blind, three arm placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery (NCT05447559)

Currently recruiting

MAD-NOCA

Multivessel compared to Single Vessel Functional Angiography to Diagnose Patients with No Obstructive Coronary Artery Disease: The MAD-NOCA trial (ACTRN12622001521718)

Currently recruiting

NADOM

NADOM trial – Neoadjuvant/ Adjuvant trial of Darovasertib in Ocular Melanoma (NCT05187884)

No longer recruiting

Vista Study

Navitor Post-Market Clinical Follow Up Study [VISTA Study] (NCT06008080)

Coming soon

NIMBLE

Non-inferiority study of GSK3511294 compared with mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotype (NCT04718389)

Recently completed/closed

PREVAIL

Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies (NCT05142722)

Currently recruiting
23 24 25 26 27